A phase-2-study, pivotal for clinical development of lanadelumab for treatment of COVID-19

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Radboud University Medical Center
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



Project description COVID-19 can lead to fluid in the lungs causing oxygen deficiency. When this is present for a long time, it can lead to intensive care (IC) admission and eventually death. There are indications that the virus disrupts the regulation of blood vessel wall permeability because the virus reduces the function of the protein angiotensin converting enzyme 2 (ACE2). As a result, produced quinines can no longer be broken down at the site of the infection. Quinines can make the blood vessel wall permeable to moisture. Research and expected outcomes This study investigates whether inhibiting the production of quinines with the drug lanadelumab can lead to a rapid recovery from oxygen deficiency. The aim of this treatment is to prevent an ICU admission if patients are admitted to hospital and have signs of fluid in the lungs and oxygen deprivation. If there is a clear effect, the strategy to inhibit the quinine system in COVID-19 will be investigated in larger trials.